Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope.
J Virol
; 75(9): 4165-75, 2001 May.
Article
de En
| MEDLINE
| ID: mdl-11287566
ABSTRACT
Vaccine-elicited antibodies specific for the third hypervariable domain of the surface gp120 of human immunodeficiency virus type 1 (HIV-1) (V3 loop) were assessed for their contribution to protection against infection in the simian-human immunodeficiency virus (SHIV)/rhesus monkey model. Peptide vaccine-elicited anti-V3 loop antibody responses were examined for their ability to contain replication of SHIV-89.6, a nonpathogenic SHIV expressing a primary patient isolate HIV-1 envelope, as well as SHIV-89.6P, a pathogenic variant of that virus. Low-titer neutralizing antibodies to SHIV-89.6 that provided partial protection against viremia following SHIV-89.6 infection were generated. A similarly low-titer neutralizing antibody response to SHIV-89.6P that did not contain viremia after infection with SHIV-89.6P was generated, but a trend toward protection against CD4+ T-lymphocyte loss was seen in these infected monkeys. These observations suggest that the V3 loop on some primary patient HIV-1 isolates may be a partially effective target for neutralizing antibodies induced by peptide immunogens.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Fragments peptidiques
/
Vaccins synthétiques
/
Anticorps anti-VIH
/
Protéine d'enveloppe gp120 du VIH
/
VIH-1 (Virus de l'Immunodéficience Humaine de type 1)
/
Virus de l'immunodéficience simienne
/
Vaccins contre le SIDA
Limites:
Animals
/
Humans
Langue:
En
Journal:
J Virol
Année:
2001
Type de document:
Article
Pays d'affiliation:
États-Unis d'Amérique